Results Release and Webinar Discussion on Morning of December 18, 2025MISSISSAUGA, Ontario, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its fourth quarter of fiscal 2025 ended September 30, 2025 (“Q4 2025”) prior to the start of trading on December 18, 2025. At 10:00 AM ET that d ...

For Repurchase of up to 5% of its outstanding shares over 12 monthsMISSISSAUGA, Ontario, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®) (“Microbix” or the “Company”), a life sciences innovator, manufacturer, and exporter, announces the initiation of a Normal Course Issuer Bid (“NCIB”) program for the repurchase and cancellation of outstanding common shares. Specifically, the NCIB enables Microbix to repurchase up to 6,949,346 Common Shares ("Shares"), that num ...

Core Insights - Microbix Biosystems Inc. is addressing a cybersecurity incident involving a ransomware attack that resulted in data theft but did not disrupt operations [1][2][3] - The company has been enhancing its cybersecurity measures since early 2022, including the implementation of advanced software systems [4][8] - Microbix has a policy of not paying ransoms to hackers, aiming to discourage cybercrime [4] Company Overview - Microbix is a life sciences innovator focused on creating proprietary biological products for human health, with over 120 employees and monthly revenues targeting C$ 2.0 million or more [5][6] - The company manufactures critical ingredients for the global diagnostics industry, including antigens for immunoassays and quality assessment products [5] - Microbix's products are sold in over 30 countries and are supported by a network of international distributors [5] Cybersecurity Measures - The company has adopted the Center for Internet Security (CIS) frameworks for its cybersecurity programs [8] - Regular employee cybersecurity training and endpoint server protection for real-time threat monitoring are part of the ongoing improvements [8] - Microbix is also focusing on disaster-recovery and business-continuity planning [8]

Core Insights - Microbix Biosystems Inc. will present to investors at the Muskoka Capital Event from September 26 to 28, 2025, focusing on growth-oriented investors [1][2] - The company aims to engage in 18 one-on-one meetings with investors during the event [2] - Microbix generates revenues targeting C$ 2.0 million or more per month and employs over 120 skilled employees [3] Company Overview - Microbix specializes in proprietary biological products for human health, particularly in the global diagnostics industry [3] - The company produces critical ingredients such as antigens for immunoassays and laboratory quality assessment products (QAPs™) [3] - Microbix's products are sold in over 30 countries, supported by a network of international distributors [3] - The company is ISO 9001 & 13485 accredited and registered with U.S. FDA, Australian TGA, and Health Canada [3] Product Development - Microbix develops proprietary products including Kinlytic® urokinase, a biologic thrombolytic drug, and reagents for molecular diagnostic testing [4] - The company’s QAPs and QUANTDx products support clinical lab accreditation and diagnostic workflows [3][4] Event Information - The Muskoka Capital Event is organized by Capital Event Management Ltd., featuring public and private companies and a range of investors [5] - The event aims to foster relationships that lead to financings and increased awareness within the investment community [5]

Core Insights - Microbix Biosystems Inc. hosted Ontario's Minister of Public and Business Service Delivery and Procurement, Stephen Crawford, to showcase its biotechnology facilities and discuss advancements in diagnostics that can enhance health outcomes and reduce healthcare costs for Ontarians [1][2] - The company has received over C$ 2.0 million in grant funding from the Ontario Together Funds, which has supported the development of state-of-the-art manufacturing capabilities and healthcare products [1][3] - Microbix supplied over 2 million units of Viral Transport Medium (VTM) to Ontario during the pandemic years of 2021 and 2022, including a significant emergency order of 1.2 million units in December 2021 [1] Company Overview - Microbix is an Ontario-based life sciences innovator with over 120 skilled employees, producing proprietary biological products for human health [3][4] - The company manufactures critical ingredients for the global diagnostics industry, including antigens for immunoassays and laboratory quality assessment products (QAPs™) [3] - Microbix's products are distributed in over 30 countries and are supported by a network of international distributors, with various accreditations including ISO 9001 & 13485 and U.S. FDA registration [3][4] Product Development - Microbix develops proprietary products such as Kinlytic urokinase, a thrombolytic drug for treating blood clots, and reagents for molecular diagnostic testing [4] - The company emphasizes its commitment to innovation and the development of Ontario-made products that contribute to global health [2][3]

Core Insights - Microbix Biosystems Inc. has launched QUANTDx™, a new product line of reference materials aimed at supporting diagnostic assay manufacturers [1][2] - The QUANTDx product line includes over 80 reference materials covering six common disease panels, addressing a critical need in the infectious disease diagnostics industry [2][3] - The launch is expected to drive revenue growth and expand Microbix's global customer base, reflecting strong demand for high-quality reference materials [4] Company Overview - Microbix Biosystems Inc. specializes in creating proprietary biological products for human health, with a revenue target of C$ 2.0 million or more per month [5] - The company offers a range of critical ingredients and devices for the global diagnostics industry, including antigens for immunoassays and quality assessment products [5][6] - Microbix is ISO 9001 & 13485 accredited and registered with U.S. FDA, Australian TGA, and Health Canada, ensuring compliance with international standards [5] Product Details - QUANTDx features accurately-quantified and fully-traceable reference materials that help assay developers establish key analytical performance metrics essential for regulatory submissions [2][3] - The product line complements Microbix's existing Quality Assessment Products (QAPs™) portfolio, enhancing support throughout the diagnostic development lifecycle [3] - The initial launch of QUANTDx addresses the need for reliable and standardized reference materials in the diagnostics industry [2][3]

Core Insights - Microbix Biosystems Inc. will present its H5N1 pandemic preparedness results at the ADLM conference in Chicago from July 28 to 31, 2025 [1][2] - The company will showcase its quality assessment products (QAPs™) that ensure the accuracy of antigen and molecular tests [2][3] - A pilot External Quality Assessment (EQA) program will be presented, focusing on the detection of the H5N1 strain using existing molecular tests [3][4] Company Overview - Microbix is a life sciences innovator with over 120 employees and aims for revenues of C$ 2.0 million or more per month [6] - The company specializes in proprietary biological products for human health, including antigens for immunoassays and QAPs that support clinical lab proficiency testing [6][7] - Microbix's QAPs are available in over 30 countries and are supported by a network of international distributors [6] Product Development - The H5N1 QAPs were developed to ensure full genetic coverage of potential pandemic strains and are available in liquid and FLOQSwab formats [5] - The collaboration with American Proficiency Institute (API) is crucial for evaluating the performance of flu tests in detecting H5N1 [4][5] - The company emphasizes the rapid deployment of its capabilities in response to emerging pandemics [5]

Core Insights - Microbix Biosystems Inc. is participating in the 2nd Asia Pacific Conference on Point of Care Testing for Infectious Diseases in Bangkok, showcasing its quality assessment products (QAPs) for point-of-care testing [1][2] Group 1: Conference Participation and Presentation - The conference aims to enhance access to rapid diagnostic tools for infectious diseases and features innovations in point-of-care testing [2] - Microbix will present a poster titled "Addressing QC Challenges in Point-of-Care Infectious Disease Testing," highlighting the use of nearly 60,000 QAPs supporting SARS-CoV-2 tests over three years [3] Group 2: Product and Market Impact - Microbix's QAPs have demonstrated reliable quality management system support across diverse usage settings, contributing to its selection as a key quality control device for the EPICC partnership aimed at HPV elimination in the Indo-Pacific [3] - The company is targeting revenues of C$ 2.0 million or more per month and has a presence in over 30 countries through international distributors [5] Group 3: Future Business Development - Discussions with diagnostics program managers and manufacturers are scheduled at the conference to expand Microbix's role in more point-of-care testing programs [4] - Microbix's QAPs are essential for clinical lab proficiency testing and are sold to various stakeholders in the diagnostics industry [5]

Core Insights - Microbix Biosystems Inc. reported Q2 and H1 fiscal 2025 results, showing a mixed performance with improved gross margins but a decline in overall revenues compared to the previous year [1][2][6]. Financial Performance - Q2 revenue was $5.3 million, a 5% decrease from $5.6 million in Q2 2024, with antigen revenues increasing by 5% to $4.3 million, while QAPs revenues fell by 38% to $864,320 due to delays in assay-development programs [3][10]. - H1 revenue totaled $11.4 million, a 19% decrease from $14.0 million in H1 2024, influenced by the absence of $4.1 million in Kinlytic licensing payments; excluding this, revenues increased by 14% [6][8]. - Gross margin for Q2 improved to 60% from 53% in the previous year, driven by better manufacturing efficiencies and pricing strategies [4][10]. - H1 gross margin was 61%, slightly down from 65% in H1 2024, but improved by 10% when excluding the impact of Kinlytic licensing revenues [7]. Operating Expenses and Income - Operating expenses in Q2 increased by 21% compared to Q2 2024, primarily due to higher investments in R&D and sales and marketing [4][10]. - Q2 net income was $20,664, a significant drop from $377,730 in Q2 2024, while H1 net income was $877,627 compared to $2.8 million in H1 2024, largely due to the absence of Kinlytic licensing fees [5][8]. Cash Position and Liquidity - Cash and equivalents at the end of Q2 stood at $14.5 million, an increase of $1.5 million from the previous quarter, despite debt repayments and share repurchases [5][10]. - The current ratio improved to 9.68, and the debt to equity ratio decreased to 0.27, indicating enhanced financial strength [9][10]. Business Outlook - Management expressed a cautious outlook for the second half of fiscal 2025, particularly for the Antigens business, due to reduced sales into China [2][11].

Company Overview - Microbix Biosystems Inc. is a life sciences innovator, manufacturer, and exporter, focusing on proprietary biological products for human health [4] - The company has over 120 skilled employees and is targeting revenues of C$ 2.0 million per month [4] - Microbix specializes in critical ingredients and devices for the global diagnostics industry, including antigens for immunoassays and laboratory quality assessment products (QAPs™) [4] Financial Results Announcement - Microbix plans to file its financial statements and results for the second quarter of fiscal 2025, which ended on March 31, 2025, before trading starts on May 15, 2025 [1] - A webinar discussion regarding the Q2 2025 results will be held at 11:00 AM ET on the same day, featuring the CEO, CFO, and COO [1] Webinar Participation - Investors and shareholders can participate in the webinar hosted by Adelaide Capital by registering online [2] - The webinar will also be live-streamed on YouTube, and a replay will be available on Adelaide Capital's YouTube channel [2][3] Product and Market Reach - Microbix's antigens are utilized by approximately 100 diagnostics manufacturers, and its QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs [4] - The QAPs are available in over 30 countries, supported by a network of international distributors [4] - The company is ISO 9001 & 13485 accredited and registered with U.S. FDA, Australian TGA, and Health Canada [4]